The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma

The Risk of Developing Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma: A SEER-based Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06659224

Enrollment

2631

Registered

2024-10-26

Start date

2000-01-01

Completion date

2021-12-30

Last updated

2025-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia (AML), Ewing Sarcoma

Keywords

acute myeloid leukemia, Ewing sarcoma, SEER

Brief summary

Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with Ewing sarcoma * Latency exclusion period of 6 months * Sequence 0 or 1

Exclusion criteria

* patients lacking age documentation or age reported only on death certificates or autopsies

Design outcomes

Primary

Measure	Time frame	Description
The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients	from Jan, 2000 till Dec, 2021	The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.

Secondary

Measure	Time frame
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups	from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages	from Jan, 2000 till Dec, 2021

Countries

Egypt

Outcome results